German pharmaceutical company URSAPHARM expands to Greece

The German pharmaceutical institution URSAPHARM is investing successful Greece, launching commercialized operations successful January 2026 done the constitution of a subsidiary successful Greece and Cyprus, under the enactment of Managing Director Greece & Cyprus Ioannis Bessis.

URSAPHARM was founded successful 1974 arsenic a household concern by two pharmacists. Today, Frank Holzer and Dominik Holzer, who pb the company, correspond the 2nd and third generations managing the household enterprise. Since its establishment, the institution has evolved into a globally operating radical with innovative products and patents, employing much than 1,200 radical worldwide.

With its ain subsidiaries successful France, the Benelux countries, Austria, Poland, the Czech Republic, Slovakia, Portugal, Russia, India, Italy, Serbia and Switzerland, arsenic well arsenic partnerships with organisation partners successful much than 80 countries, URSAPHARM has developed into a truly planetary player, reporting income of 400 cardinal euros successful 2025 and yearly maturation of 8%–12%.

In Greece, its archetypal merchandise offering includes the HYLO ophthalmic range, with further products from its portfolio expected to travel shortly. Beyond treatments for oculus conditions, the company’s portfolio besides includes wide medicine products for the nasal mucosa, seasonal allergies, dietary supplements and dermocosmetics.

According to Bessis, the institution aims to physique partnerships with the technological assemblage and grow its portfolio, while an further state is expected to beryllium included under this absorption structure alongside Greece and Cyprus.